High Death Risk Tied to mTOR Drugs in Cancer ( rapamycin)

Blogger's Note: clinical trials in renal (kidney) and other cancers

High Death Risk Tied to mTOR Drugs in Cancer

Action Points

• This study was published as an abstract and presented at a conference. These data and conclusions should be considered to be preliminary until published in a peer-reviewed journal.
• Fatal adverse events occurred more than twice as often in cancer patients treated with mammalian target of rapamycin (mTOR) inhibitors compared with control therapies.
• Point out that the most commonly identified cause of death was sepsis/infection.